SLE clinical trials: impact of missing data on estimating treatment effects

被引:9
作者
Kim, Mimi [1 ]
Merrill, Joan T. [2 ]
Wang, Cuiling [1 ]
Viswanathan, Shankar [1 ]
Kalunian, Ken [3 ]
Hanrahan, Leslie [4 ]
Izmirly, Peter [5 ]
机构
[1] Albert Einstein Coll Med, Epidemiol & Populat Hlth, Bronx, NY 10467 USA
[2] Oklahoma Med Res Fdn, Arthrit & Clin Immunol Program, 825 NE 13th St, Oklahoma City, OK 73104 USA
[3] Univ Calif San Diego, Rheumatol, San Diego, CA USA
[4] Lupus Fdn Amer, Res & Educ, Washington, DC USA
[5] NYU, Sch Med, Div Rheumatol, Med, New York, NY USA
关键词
MULTIPLE IMPUTATION; OUTCOMES;
D O I
10.1136/lupus-2019-000348
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective A common problem in clinical trials is missing data due to participant dropout and loss to follow-up, an issue which continues to receive considerable attention in the clinical research community. Our objective was to examine and compare current and alternative methods for handling missing data in SLE trials with a particular focus on multiple imputation, a flexible technique that has been applied in different disease settings but not to address missing data in the primary outcome of an SLE trial. Methods Data on 279 patients with SLE randomised to standard of care (SoC) and also receiving mycophenolate mofetil (MMF), azathioprine or methotrexate were obtained from the Lupus Foundation of America-Collective Data Analysis Initiative Database. Complete case analysis (CC), last observation carried forward (LOCF), non-responder imputation (NRI) and multiple imputation (MI) were applied to handle missing data in an analysis to assess differences in SLE Responder Index-5 (SRI-5) response rates at 52 weeks between patients on SoC treated with MMF versus other immunosuppressants (non-MMF). Results The rates of missing data were 32% in the MMF and 23% in the non-MMF groups. As expected, the NRI missing data approach yielded the lowest estimated response rates. The smallest and least significant estimates of differences between groups were observed with LOCF, and precision was lowest with the CC method. Estimated between-group differences were magnified with the MI approach, and imputing SRI-5 directly versus deriving SRI-5 after separately imputing its individual components yielded similar results. Conclusion The potential advantages of applying MI to address missing data in an SLE trial include reduced bias when estimating treatment effects, and measures of precision that properly reflect uncertainty in the imputations. However, results can vary depending on the imputation model used, and the underlying assumptions should be plausible. Sensitivity analysis should be conducted to demonstrate robustness of results, especially when missing data proportions are high.
引用
收藏
页数:7
相关论文
共 29 条
[1]  
[Anonymous], 2004, Multiple imputation for nonresponse in surveys
[2]  
[Anonymous], 2010, PREV TREATM MISS DAT
[3]   Multiple imputation by chained equations: what is it and how does it work? [J].
Azur, Melissa J. ;
Stuart, Elizabeth A. ;
Frangakis, Constantine ;
Leaf, Philip J. .
INTERNATIONAL JOURNAL OF METHODS IN PSYCHIATRIC RESEARCH, 2011, 20 (01) :40-49
[4]   Missing data in randomized controlled trials of rheumatoid arthritis with radiographic outcomes: A simulation study [J].
Baron, Gabriel ;
Ravaud, Philippe ;
Samson, Adeline ;
Giraudeau, Bruno .
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2008, 59 (01) :25-31
[5]   Handling missing data in RCTs; a review of the top medical journals [J].
Bell, Melanie L. ;
Fiero, Mallorie ;
Horton, Nicholas J. ;
Hsu, Chiu-Hsieh .
BMC MEDICAL RESEARCH METHODOLOGY, 2014, 14
[6]   Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials [J].
Clowse, Megan E. B. ;
Wallace, Daniel J. ;
Furie, Richard A. ;
Petri, Michelle A. ;
Pike, Marilyn C. ;
Leszczynski, Piotr ;
Neuwelt, C. Michael ;
Hobbs, Kathryn ;
Keiserman, Mauro ;
Duca, Liliana ;
Kalunian, Kenneth C. ;
Galateanu, Catrinel ;
Bongardt, Sabine ;
Stach, Christian ;
Beaudot, Carolyn ;
Kilgallen, Brian ;
Gordon, Caroline .
ARTHRITIS & RHEUMATOLOGY, 2017, 69 (02) :362-375
[7]   A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus [J].
Furie, Richard ;
Petri, Michelle ;
Zamani, Omid ;
Cervera, Ricard ;
Wallace, Daniel J. ;
Tegzova, Dana ;
Sanchez-Guerrero, Jorge ;
Schwarting, Andreas ;
Merrill, Joan T. ;
Chatham, W. Winn ;
Stohl, William ;
Ginzler, Ellen M. ;
Hough, Douglas R. ;
Zhong, Z. John ;
Freimuth, William ;
van Vollenhoven, Ronald F. .
ARTHRITIS AND RHEUMATISM, 2011, 63 (12) :3918-3930
[8]   Missing Data Analysis: Making It Work in the Real World [J].
Graham, John W. .
ANNUAL REVIEW OF PSYCHOLOGY, 2009, 60 :549-576
[9]   Auxiliary variables in multiple imputation in regression with missing X: a warning against including too many in small sample research [J].
Hardt, Jochen ;
Herke, Max ;
Leonhart, Rainer .
BMC MEDICAL RESEARCH METHODOLOGY, 2012, 12
[10]   Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study [J].
Isenberg, D. A. ;
Petri, M. ;
Kalunian, K. ;
Tanaka, Y. ;
Urowitz, M. B. ;
Hoffman, R. W. ;
Morgan-Cox, M. ;
Iikuni, N. ;
Silk, M. ;
Wallace, D. J. .
ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 (02) :323-331